Trial Profile
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Luminespib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 29 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Feb 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 02 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.